CN1486988A - Mannuronic oligose with carboxyl group in reduction end position-1 and its derivative - Google Patents
Mannuronic oligose with carboxyl group in reduction end position-1 and its derivative Download PDFInfo
- Publication number
- CN1486988A CN1486988A CNA031389767A CN03138976A CN1486988A CN 1486988 A CN1486988 A CN 1486988A CN A031389767 A CNA031389767 A CN A031389767A CN 03138976 A CN03138976 A CN 03138976A CN 1486988 A CN1486988 A CN 1486988A
- Authority
- CN
- China
- Prior art keywords
- derivative
- mannuronic
- oligose
- acid
- carboxyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
The present invention relates to mannuronic oligose and its derivative, and is especially mannuronic oligose and its derivative with carboxyl group in the place 1 of the reduction end. During the preparation, mannuronic oligose or its derivative is compounded into water solution, added with oxidant to concentration of 1-15% and reacted at 30-120 deg.c; and after reaction, the reacted liquid is separated and purified with Biogel P 10 and Sax chromatographic column to obtain mannuronic oligose or its derivative with carboxyl group in the place 1 of the reduction end. The present invention provides one serial of new compounds with special functions and activity for wide application, and the present invention also provides direct evidence for deeply understanding polysaccharide degrading mechanism.
Description
Technical field:
The present invention relates to 1 of a kind of reducing end and be the algin oligosaccharide of carboxyl and derivative thereof.
Background technology:
Algin is the linear anionic polysaccharide that is connected to form by 1,4 glycosidic link by beta-D-mannuronic acid and α-L-guluronic acid.Above-mentioned two kinds of uronic acid homogeneous or alternately arrangement, the algin fragment that homogeneous is arranged comprises polymannuronic acid (PM) and poly-guluronic acid (PG).The algin source is abundant, and has been widely used in food, chemical industry and pharmaceutical sector etc.Algin oligosaccharide comprised that the physiological action of mannuronic acid oligosaccharide and derivative thereof constantly was found in recent years, and it has the function of stronger promotion plant-growth; Anticoagulant active is arranged; Antiviral activity; Anti-microbial activity; Improve immunizing power, anti-tumor activity and anti-inflammatory activity.Therefore the demand of mannuronic acid oligosaccharide and derivative thereof grows with each passing day, and has caused the concern that people are bigger.
Summary of the invention:
The purpose of this invention is to provide 1 of a kind of reducing end and be the mannuronic acid oligosaccharide of carboxyl and derivative thereof, it can satisfy the demand of prior art.
A kind of mannuronic acid oligosaccharide and derivative thereof is characterized in that 1 of this mannuronic acid oligosaccharide and derivative reducing end thereof are carboxyl, and structural formula is as follows:
N is 1-19 in the formula; R all can be H or HSO
3Or OCCH
3Or H
2PO
3
A kind of 1 method of reducing end of making for the mannuronic acid oligosaccharide of carboxyl and derivative thereof, comprise and the polymannuronic acid or derivatives thereof is made into 1～25% the aqueous solution, add oxygenant to final concentration 1～15%, 30～120 ℃ of reactions down, after it is characterized in that the stopping of reaction, reaction solution Bio-gel P10, the separation and purification of Sax chromatography column.
Advantage of the present invention is: a series of new compounds are provided, and their function and activity can be widely used, and also provide direct evidence for the mechanism of further in depth being familiar with the oxidative degradation polysaccharide.
Embodiment:
The polymannuronic acid or derivatives thereof is made into 1～25% (by weight, as follows) the aqueous solution, add oxygenant to final concentration 1～15%, 30～120 ℃ of reactions down, after it is characterized in that the stopping of reaction, reaction solution Bio-gel P10, the separation and purification of Sax chromatography column obtains 1 of reducing end and is the mannuronic acid oligosaccharide of carboxyl and derivative thereof.Its structural formula is:
N is 1-19 in the formula; R all can be H or HSO
3Or OCCH
3Or H
2PO
3
Oxygenant described in the present invention is hydrogen peroxide, hypochlorous acid, hypochlorite or sulfuric acid.Described polymannuronic acid and derivative thereof comprise many or oligomerization mannuronic acid, many or oligomerization mannuronic acid sulfation, phosphorylation, ethyl esterization or esterification derivative.
Claims (4)
1. mannuronic acid oligosaccharide and derivative thereof is characterized in that 1 of this mannuronic acid oligosaccharide and derivative reducing end thereof are carboxyl, and its structural formula is:
N is 1-19 in the formula; R all can be H or HSO
3Or OCCH
3Or H
2PO
3
2. make 1 method of reducing end for one kind for the mannuronic acid oligosaccharide of carboxyl and derivative thereof, comprise and the polymannuronic acid or derivatives thereof is made into 1～25% the aqueous solution, add oxygenant to final concentration 1～15%, 30～120 ℃ of reactions down, after it is characterized in that the stopping of reaction, reaction solution Bio-gel P10, the separation and purification of Sax chromatography column.
3. method as claimed in claim 2 is characterized in that described oxygenant is hydrogen peroxide, hypochlorous acid, hypochlorite or sulfuric acid.
4. method as claimed in claim 2 is characterized in that described polymannuronic acid and derivative thereof comprise many or oligomerization mannuronic acid, many or oligomerization mannuronic acid sulfation, phosphorylation, ethyl esterization or esterification derivative.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031389767A CN1486988A (en) | 2003-08-04 | 2003-08-04 | Mannuronic oligose with carboxyl group in reduction end position-1 and its derivative |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031389767A CN1486988A (en) | 2003-08-04 | 2003-08-04 | Mannuronic oligose with carboxyl group in reduction end position-1 and its derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1486988A true CN1486988A (en) | 2004-04-07 |
Family
ID=34154992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA031389767A Pending CN1486988A (en) | 2003-08-04 | 2003-08-04 | Mannuronic oligose with carboxyl group in reduction end position-1 and its derivative |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1486988A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005089776A1 (en) * | 2004-03-24 | 2005-09-29 | Ocean University Of China | Algin oligosaccharides and the derivatives thereof as well as the manufacture and the use of the same |
| CN106349298A (en) * | 2015-07-17 | 2017-01-25 | 上海绿谷制药有限公司 | Application of sodium alginate oligose and derivative to improvement of sleep disorders |
| CN113181207A (en) * | 2021-02-06 | 2021-07-30 | 中国海洋大学 | Use of oligomannuronic acid phosphate for the preparation of a medicament for the prevention and treatment of novel coronavirus infections |
-
2003
- 2003-08-04 CN CNA031389767A patent/CN1486988A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005089776A1 (en) * | 2004-03-24 | 2005-09-29 | Ocean University Of China | Algin oligosaccharides and the derivatives thereof as well as the manufacture and the use of the same |
| EA011417B1 (en) * | 2004-03-24 | 2009-02-27 | Оушн Юниверсити Оф Чайна | Algin oligosaccharides and the derivatives thereof, the manufacture and the use of the same |
| US8835403B2 (en) | 2004-03-24 | 2014-09-16 | Meiyu Geng | Algin oligosaccharides and the derivatives thereof as well as the manufacture and the use of the same |
| US9493496B2 (en) | 2004-03-24 | 2016-11-15 | Ocean University Of China | Algin oligosaccharides and the derivatives thereof as well as the manufacture and the use of the same |
| US10213456B2 (en) | 2004-03-24 | 2019-02-26 | Ocean University Of China | Alginate oligosaccharides and the derivatives thereof as well as the manufacture and the use of the same |
| CN106349298A (en) * | 2015-07-17 | 2017-01-25 | 上海绿谷制药有限公司 | Application of sodium alginate oligose and derivative to improvement of sleep disorders |
| CN113181207A (en) * | 2021-02-06 | 2021-07-30 | 中国海洋大学 | Use of oligomannuronic acid phosphate for the preparation of a medicament for the prevention and treatment of novel coronavirus infections |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0116801B1 (en) | Depolymerized and supersulfated heparin, process for its preparation and pharmaceutical compositions containing them | |
| KR100853585B1 (en) | Heparin-derived polysaccharide mixtures, preparation method and pharmaceutical compositions containing same | |
| CN1241932C (en) | Novel oligosaccharides, preparation method and pharmaceutical composition containing same | |
| HU203565B (en) | Process for producing heparin, heparane-sulfat and dermatane-sulfat of small molecular mass and pharmaceutical compositions containing them as active components | |
| JP5021898B2 (en) | Heparin-derived polysaccharide mixture, its production and pharmaceutical composition containing it | |
| CN103665057B (en) | A kind of synthetic method of Bromotetraacetylgluc,se | |
| CN101962415A (en) | Method for preparing low molecular weight brown seaweed fucoidan sulfate | |
| KR910006809B1 (en) | Process for the preparation of neutral heparan sulphate and dermatan sulphate | |
| CN109937208B (en) | Preparation method of oligomannuronic acid | |
| CN1486988A (en) | Mannuronic oligose with carboxyl group in reduction end position-1 and its derivative | |
| CN1473836A (en) | Guluronic acid oligose with carboxylic acid at reducing end positiion-1 and its derivatives | |
| CN101942039B (en) | Parnaparin production method | |
| CN103601766B (en) | Fondaparinux sodium pentasaccharide intermediate and preparation method thereof | |
| CN1675250B (en) | Epimerized derivatives of K5 polysaccharide with a very high degree of sulfation | |
| CN1219784C (en) | Mannuronic acid oligosaccharides production method utilizing Fenton-type reaction | |
| CN1219786C (en) | Guluronicacid oligosaccharides production method utilizing Fenton-type reaction | |
| CN1485329A (en) | Glycoca uronic acid oligosaccharide with reducing end of 1-carboxyl and its derivative | |
| CN1219785C (en) | Glycoca uronic acid oligosaccharides production method utilizing Fenton-type reaction | |
| WO2008113918A1 (en) | Heparins including at least one covalent bond with biotin or a biotin derivative, method for preparing same and use thereof | |
| NZ544717A (en) | Heparin-derived oligosaccharide mixtures, preparation thereof and pharmaceutical compositions containing said mixtures | |
| CN1212328C (en) | Preparation method of fucosan sulphate oligosaccharide | |
| WO1999043714A1 (en) | Novel polysaccharide derivatives, process for the production thereof and medicinal compositions containing the same as the active ingredient | |
| CN105884934A (en) | Preparation method of dalteparin sodium | |
| CN100404541C (en) | Method for preparing z-deoxy-D-glucose | |
| CN106749758A (en) | Diluted alkaline-enzymolysis-resin adsorption extraction method extracts the chondroitin sulfate in hog snout bone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |